Pharma and BioTech Daily: Trump's Tariff Deadline, FDA Approvals, and Price-Lowering Efforts
Podcast: Pharma and BioTech Daily
Host: Pharma and BioTech News
Episode Date: September 29, 2025
Episode Overview
This episode focuses on significant policy and regulatory updates affecting the pharmaceutical and biotech industries. Major stories include the Trump administration’s new tariff deadline for pharmaceutical companies, notable FDA approvals, and broader government initiatives aimed at reducing drug prices and improving patient access.
Key Discussion Points & Insights
1. Trump’s 100% Tariff Deadline for Pharmaceutical Companies
[00:08]
- President Trump announced a forthcoming 100% tariff on pharmaceutical companies, set to begin on October 1.
- Exemption: Companies already building manufacturing facilities in the United States will not be subject to these tariffs.
- Administrative Goal: This initiative is part of a larger strategy to:
- Lower drug prices.
- Increase domestic production.
- Improve access to medication for American patients.
Quote:
“President Trump has announced a 100% tariff deadline for pharmaceutical companies starting on October 1. However, companies that have already begun construction on manufacturing facilities in the US are exempt from these tariffs.”
— Host [00:09]
2. FDA Approvals: Spotlight on New Treatments
A. Kinetics Pharmaceuticals’ Approval for Acromegaly
[00:33]
- The FDA approved a once-daily treatment for acromegaly, a rare pituitary disorder, from Kinetics Pharmaceuticals.
- Marks a major milestone for both Kinetics and patients.
- The new therapy is expected to have a significant positive impact on patients’ lives.
Quote:
“This approval marks a significant milestone for Kinetics and is expected to have a positive impact on patients’ lives.”
— Host [00:40]
B. Lilly’s Oral SERD for Breast Cancer
[00:46]
- The FDA approved Lilly’s oral SERD (Selective Estrogen Receptor Degrader) for breast cancer.
- Clinical results show improved progression-free survival compared to standard therapy.
- Offers renewed hope for breast cancer patients.
Quote:
“This treatment has shown improved progression free survival compared to standard therapy, offering new hope for patients battling this disease.”
— Host [00:55]
3. Continued US Efforts to Lower Drug Prices
[01:05]
- In addition to the tariff, the Trump administration is preparing a proposed rule focused on lowering drug prices.
- Objective: Bring US drug costs in line with those in other economically similar countries.
- Moves are representative of an ongoing commitment to affordability and access.
Quote:
“The Trump administration is also preparing a proposed rule to further lower drug prices in the US as part of an ongoing effort to align drug prices with other economically similar countries.”
— Host [01:09]
Notable Quotes & Moments
- On Price-Lowering Initiatives:
“These developments in the pharmaceutical industry are aimed at improving access to treatments and lowering costs for patients.”
— Host [01:18]
Timestamps of Important Segments
- 00:08 – Trump’s 100% tariff announcement & exemptions
- 00:33 – Kinetics Pharmaceuticals FDA approval for acromegaly
- 00:46 – Lilly’s oral SERD approval for breast cancer
- 01:05 – Administration’s proposed rule on drug pricing
- 01:18 – Summary emphasis on patient benefits
Episode Tone & Language
The episode maintains a focused, urgent, and informative tone, emphasizing impact, innovation, and policy change. The host delivers concise updates geared toward industry stakeholders, health professionals, and patients eager to understand shifting pharma and biotech landscapes.
Summary:
This episode presents an essential overview of emerging pharma and biotech policy, groundbreaking FDA drug approvals, and the US government's latest efforts in making life-saving treatments more affordable and accessible for all.